S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
"Prepare for Five Years of Famine" (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
What To Do With Your Trades Today (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
What To Do With Your Trades Today (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
"Prepare for Five Years of Famine" (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
What To Do With Your Trades Today (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
What To Do With Your Trades Today (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
"Prepare for Five Years of Famine" (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
What To Do With Your Trades Today (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
What To Do With Your Trades Today (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
"Prepare for Five Years of Famine" (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
What To Do With Your Trades Today (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
What To Do With Your Trades Today (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
NASDAQ:DNLI

Denali Therapeutics - DNLI Stock Forecast, Price & News

$23.04
+1.13 (+5.16%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$21.96
$23.11
50-Day Range
$21.91
$32.67
52-Week Range
$20.24
$39.43
Volume
1.10 million shs
Average Volume
684,416 shs
Market Capitalization
$3.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.58

Denali Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
136.9% Upside
$54.58 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$2.69 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.48) to ($3.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Medical Sector

72nd out of 1,004 stocks

Biological Products, Except Diagnostic Industry

13th out of 166 stocks


DNLI stock logo

About Denali Therapeutics (NASDAQ:DNLI) Stock

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DNLI Stock News Headlines

Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Where Denali Therapeutics Stands With Analysts
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Heska (HSKA) Earnings Expected to Grow: Should You Buy?
Expert Ratings for Denali Therapeutics
Let's Take a Technical Peek at Denali Therapeutics
Denali Slumps on Drug Candidate Tests
See More Headlines
Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DNLI Company Calendar

Last Earnings
2/27/2023
Today
3/31/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DNLI
Fax
N/A
Employees
380
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$54.58
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+136.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
13 Analysts

Profitability

Net Income
$-325,990,000.00
Net Margins
-300.55%
Pretax Margin
-300.54%

Debt

Sales & Book Value

Annual Sales
$108.46 million
Book Value
$7.68 per share

Miscellaneous

Free Float
119,320,000
Market Cap
$3.15 billion
Optionable
Optionable
Beta
1.39

Social Links


Key Executives

  • Ryan J. WattsRyan J. Watts
    President, Chief Executive Officer & Director
  • Alexander O. SchuthAlexander O. Schuth
    Secretary, Chief Operating & Financial Officer
  • Carole HoCarole Ho
    Chief Medical Officer & Head-Development
  • Dana Andersen
    CTO & Chief Manufacturing Officer
  • Joe Lewcock
    Chief Scientific Officer













DNLI Stock - Frequently Asked Questions

Should I buy or sell Denali Therapeutics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DNLI shares.
View DNLI analyst ratings
or view top-rated stocks.

What is Denali Therapeutics' stock price forecast for 2023?

13 analysts have issued 12 month price objectives for Denali Therapeutics' shares. Their DNLI share price forecasts range from $32.00 to $105.00. On average, they expect the company's share price to reach $54.58 in the next year. This suggests a possible upside of 136.9% from the stock's current price.
View analysts price targets for DNLI
or view top-rated stocks among Wall Street analysts.

How have DNLI shares performed in 2023?

Denali Therapeutics' stock was trading at $27.81 at the beginning of 2023. Since then, DNLI stock has decreased by 17.2% and is now trading at $23.04.
View the best growth stocks for 2023 here
.

When is Denali Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our DNLI earnings forecast
.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) issued its quarterly earnings data on Monday, February, 27th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.02. The company earned $10.28 million during the quarter, compared to analyst estimates of $11.29 million. Denali Therapeutics had a negative net margin of 300.55% and a negative trailing twelve-month return on equity of 35.67%. The business's revenue was down 17.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.62) EPS.

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Denali Therapeutics own?
When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

How do I buy shares of Denali Therapeutics?

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $23.04.

How much money does Denali Therapeutics make?

Denali Therapeutics (NASDAQ:DNLI) has a market capitalization of $3.15 billion and generates $108.46 million in revenue each year. The company earns $-325,990,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

How many employees does Denali Therapeutics have?

The company employs 380 workers across the globe.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.denalitherapeutics.com. The company can be reached via phone at (615) 866-8548 or via email at hansen@dnli.com.

This page (NASDAQ:DNLI) was last updated on 4/1/2023 by MarketBeat.com Staff